August 24, 2013

AllaChem Announces the Beginning of Phase I Clinical Studies of AV4025, a Potent Small Molecule for the Treatment of Chronic Hepatitis C Infection

2013-08-05, Source: AllaChem, LLC

AllaChem, LLC announces the beginning of Phase I clinical studies of AV4025, a potent small molecule for the treatment of chronic hepatitis C infection. Hallandale Beach, Fl - July 25, 2013 - Alla Chem, LLC announced today the initiation of phase I clinical studies with AV4025, a next in-class small molecule HCV NS5A Inhibitor for the treatment of chronic hepatitis C infection. A double-blind, placebo-controlled, single ascending dose (10, 20 and 40 mg) study will evaluate safety, tolerability and pharmacokinetics of AV4025 upon oral administration in 30 healthy volunteers. The results of the pre-clinical and clinical studies will be presented at the 10th International Conference "Viral Hepatitis: Epidemiology, Diagnostics, Treatment and Prevention", September 17-19, 2013, Moscow, Russian Federation.


Alena Ivachtchenko, MBA

Director Business Development

Phone: 1-858-35-6627



"It's a Big Part of Our Lives": A Qualitative Study Defining Quality of Hepatitis C Care From the Patient's Perspective

Gastroenterol Nurs. 2013 July/August;36(4):249-257.

Brunings P, Klar S, Butt G, Nijkamp MD, Buxton JA.

About the authors: Paulien Brunings, MHSc, is Research Assistant, British Columbia Centre for Disease Control, Vancouver, British Columbia, Canada, and University of Maastricht, Maastricht, the Netherlands. Salman Klar, MPH, is Research Assistant, University of British Columbia, Vancouver, British Columbia, Canada. Gail Butt, PhD, RN, is Associate Director, Hepatitis Services, British Columbia Centre for Disease Control, and University of British Columbia, Vancouver, British Columbia, Canada. Marjan D. Nijkamp, PhD, is Docent, Open University of the Netherlands, Heerlen, the Netherlands. Jane A. Buxton, MBBS, MHSc, FRCPC, is Physician Epidemiologist and Harm Reduction Lead, British Columbia Centre for Disease Control, and Associate Professor, University of British Columbia, Vancouver, British Columbia, Canada.


Nurses play a key role in the ongoing treatment and management of chronic conditions such as Hepatitis C. Their skills in counseling, education, and as liaisons between patients, support services, and other healthcare providers make them crucial in the management of patients with Hepatitis C. Qualitative methods were used to explore and describe quality-of-care perspectives of patients receiving care in viral hepatitis clinics. Data were collected through focus group interviews at three hepatitis prevention and care demonstration projects located in underserved rural and small urban areas in British Columbia, Canada. Key themes were identified and used to construct a "Hepatitis C care model" and generate quality-of-care statements. These statements were then rated by another group of participants with Hepatitis C, using concept mapping. Most themes identified by the participants in focus groups (n = 21) related to care provision processes (autonomy, communication, education/information, continuity of care, professional competence, and support) rather than structure or outcomes of care. Concept-mapping participants (n = 20) rated communication as the key theme. Participants also highlighted the supportive role nurses played. Hepatitis C programming can be improved by leveraging nurses' strengths within multidisciplinary teams to address patient's concerns about process and communication issues.

PMID: 23899483 [PubMed - as supplied by publisher]